Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it ...

Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...

Zimmer Biomet Holdings Inc (ZBH) reports robust Q4 performance with nearly 5% constant currency revenue growth and outlines ...

Stratos Wealth Partners LTD. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.5% during the ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business with a $1.1 billion deal to acquire ...

Raymond James lowered the firm’s price target on Zimmer Biomet (ZBH) to $119 from $126 and keeps an Outperform rating on the shares. Zimmer ...

Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...

Q4 2024 Management View CEO Ivan Tornos highlighted that Zimmer Biomet achieved nearly 5% constant currency sales growth in Q4 2024, marking the 12th consecutive quarter of mid-single-digit or better ...